Eli Lilly Stock Rises on $2.4 Billion Cell Therapy Acquisition of Orna Therapeutics | MarketWire
Eli Lilly boosts its pipeline with the $2.4 billion purchase of RNA-focused Orna Therapeutics. What this means for the biotech giant and investors in 2026.